Recommended Topic Related To:

Trasylol

"The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked a"...

Trasylol

INDICATIONS

Trasylol® (aprotinin) is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.

DOSAGE AND ADMINISTRATION

Trasylol® (aprotinin) given prophylactically in both Regimen A and Regimen B (half Regimen A) to patients undergoing CABG surgery significantly reduced the donor blood transfusion requirement relative to placebo treatment. In low risk patients there is no difference in efficacy between regimen A and B. Therefore, the dosage used (A vs. B) is at the discretion of the practitioner.

Trasylol® (aprotinin) is supplied as a solution containing 10,000 KIU/mL, which is equal to 1.4 mg/mL. All intravenous doses of Trasylol® (aprotinin) should be administered through a central line. DO NOT ADMINISTER ANY OTHER DRUG USING THE SAME LINE. Both regimens include a 1 mL initial (test) dose, a loading dose, a dose to be added while recirculating the priming fluid of the cardiopulmonary bypass circuit ("pump prime" dose), and a constant infusion dose. To avoid physical incompatibility of Trasylol® (aprotinin) and heparin when adding to the pump prime solution, each agent must be added during recirculation of the pump prime to assure adequate dilution prior to admixture with the other component. Regimens A and B, both incorporating a 1 mL initial (test) dose, are described in the table below:

  INITIAL (TEST) DOSE LOADING DOSE “PUMP PRIME” DOSE CONSTANT INFUSION DOSE
TRASYLOL® REGIMEN A 1 mL
(1.4 mg, or 10,000 KIU)
200 mL
(280 mg, or 2.0 million KIU)
200 mL
(280 mg, or 2.0 million KIU)
50 mL/hr
(70 mg/hr, or 500,000 KIU/hr)
TRASYLOL® REGIMEN B 1 mL
(1.4 mg, or 10,000 KIU)
100 mL
(140 mg, or 1.0 million KIU)
100 mL
(140 mg, or 1.0 million KIU)
25 mL/hr
(35 mg/hr, or 250,000 KIU/hr)

The 1 mL initial (test) dose should be administered intravenously at least 10 minutes before the loading dose. With the patient in a supine position, the loading dose is given slowly over 20-30 minutes, after induction of anesthesia but prior to sternotomy. In patients with known previous exposure to Trasylol® (aprotinin) , the loading dose should be given just prior to cannulation. When the loading dose is complete, it is followed by the constant infusion dose, which is continued until surgery is complete and the patient leaves the operating room. The "pump prime" dose is added to the recirculating priming fluid of the cardiopulmonary bypass circuit, by replacement of an aliquot of the priming fluid, prior to the institution of cardiopulmonary bypass. Total doses of more than 7 million KIU have not been studied in controlled trials.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Discard any unused portion.

Renal and Hepatic Impairment: Trasylol® (aprotinin) administration is associated with a risk for renal dysfunction (see WARNINGS: Renal Dysfunction). Changes in aprotinin pharmacokinetics with age or impaired renal function are not great enough to require any dose adjustment. Pharmacokinetic data from patients with pre-existing hepatic disease treated with Trasylol® (aprotinin) are not available.

HOW SUPPLIED

Size Strength NDC
100 mL vials 1,000,000 KIU 0026-8196-36
200 mL vials 2,000,000 KIU 0026-8197-63

STORAGE

Trasylol® (aprotinin) should be stored between 2° and 25°C (36° - 77°F). Protect from freezing.

Bayer HealthCare
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Made in Germany
Rx Only
01298181 12/06 © 2006 Bayer Pharmaceuticals Corporation 13121 Printed in USA
FDA rev date: 12/15/06

Last reviewed on RxList: 3/16/2007
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Heart Health

Get the latest treatment options.

Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations